• About Us
    • Overview
    • Education
    • Mission & History
    • Board of Directors
    • The Campus
    • Careers
  • Our Achievements
    • Overview
    • Cancer
    • Technology
    • Education
    • Our Planet
    • Health & Medicine
    • Physical World
  • Get Involved
    • Overview
    • Partners in Science
    • Estate & Planned Giving
    • Attend an Event
    • Gift Opportunities
  • News & Media
    • Overview
    • News & Media Archive
    • Coronavirus
    • Feature Stories
    • News Releases
    • In The News
    • Video Gallery
    • Ad Campaigns
    • Celebrating Great Minds
  • Blog
  • Contact
  • Donate
Donate
Donate
About Us tri
About Us Overview
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
About Us

Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.

Our Achievements tri
Our Achievements Overview
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Our Achievements

The Weizmann Institute’s fundamental research has led to discoveries and applications with a major impact on the scientific community and on the quality of life for millions worldwide.

Get Involved tri
Get Involved Overview
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
Get Involved

Join a community of dedicated people who share the Weizmann Institute’s commitment to shaping a better world through science.

News & Media tri
News & Media Overview
  • News & Media Archive
  • Coronavirus
  • Feature Stories
  • News Releases
  • In The News
  • Video Gallery
  • Ad Campaigns
  • Celebrating Great Minds
News & Media

Learn about the Weizmann Institute’s latest groundbreaking discoveries and the American Committee’s activities across the country.

Blog tri
  • The Curiosity Review
Blog

Popular science for the curious-minded: The Curiosity Review brings discovery to life.

Contact

Search Results

  • SEARCH BY KEYWORD
  • SEARCH BY TAG
View Articles by Tag:
  • View Articles by Tag
  • Algorithims (6)
  • Alternative energy (27)
  • Alzheimers (44)
  • Archaeology (37)
  • Artificial intelligence (20)
  • Astrophysics (108)
  • Autism (22)
  • Awards (119)
  • Bacteria (107)
  • Behavior (9)
  • Biochemistry (101)
  • Biofuel (7)
  • Biology (309)
  • Biomolecular sciences (7)
  • Blood (43)
  • Brain (175)
  • Cancer (163)
  • Cancer treatment (127)
  • Central nervous system (9)
  • Chemistry (78)
  • Children (7)
  • Circadian clock (1)
  • Climate change (73)
  • Clinical trials (40)
  • Collaborations (19)
  • Community (279)
  • Computers (73)
  • Copaxone (12)
  • Coronavirus (7)
  • Culture (359)
  • Diabetes (32)
  • Earth (74)
  • Education (157)
  • Environment (92)
  • Enzymes (29)
  • Evolution (89)
  • Fertility (20)
  • Fungus (4)
  • Genetics (109)
  • Genomics (3)
  • Heart (5)
  • Heart disease (3)
  • Humanity (83)
  • Immune system (149)
  • Immunology (10)
  • Immunotherapy (34)
  • Inflammation (19)
  • Leadership (114)
  • Leukemia (12)
  • Materials (44)
  • Mathematics (62)
  • Medicine (84)
  • Memory (39)
  • Mental health (58)
  • Metabolism (51)
  • Microbiology (2)
  • Microbiome (10)
  • Molecular cell biology (9)
  • Molecular genetics (61)
  • Multiple sclerosis (12)
  • Nanoscience (33)
  • Nature (4)
  • Neurobiology (2)
  • Neuroscience (207)
  • Nutrition (72)
  • Optics (34)
  • Organs (11)
  • Parkinsons (11)
  • Personalized medicine (5)
  • Philanthropy (148)
  • Physics (139)
  • Plants (56)
  • Proteins (96)
  • Quantum computer (3)
  • Quantum physics (2)
  • Quantum theory (34)
  • Robots (8)
  • Security (21)
  • Senses (115)
  • Sensors (8)
  • Smoking (1)
  • Solar power (19)
  • Space (110)
  • Stem cells (49)
  • Technology (206)
  • Vaccine (40)
  • Virus (135)
  • Water (40)
  • Weather (1)
  • Women (115)
  • World hunger (17)
Filter by Time:
  • All
  • Past Day
  • Past Week
  • Past Month
  • Past Year
  • Past Three Years
Clear Filters

127 results for Cancer treatment

Toward an “Ultra-Personalized” Therapy for Melanoma
Toward an “Ultra-Personalized” Therapy for Melanoma

https://www.weizmann-usa.org/news-media/news-releases/toward-an-ultra-personalized-therapy-for-melanoma/

Sep 12, 2018... T cells (red) attacking melanoma cells (green). The neo-antigen-specific T cells in this image are especially effective at killing cancer cells
REHOVOT, ISRAEL—September 12, 2018—With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their ability to recognize the cancer and kill it. The results of this study were published in Cancer Discovery.

TAGS: Cancer, Biology, Cancer treatment, Proteins

October is National Breast Cancer Awareness Month
October is National Breast Cancer Awareness Month

https://www.weizmann-usa.org/news-media/feature-stories/october-is-national-breast-cancer-awareness-month-1/

Oct 16, 2019... October is National Breast Cancer Awareness Month, and people across the world are helping raise awareness and support through runs, walks, events – and, at the Weizmann Institute of Science, through research.
Before breakthroughs in breast cancer research ever appear in the news or on the market, there are cadres of scientists working tirelessly to discover new ways to prevent, diagnose, and treat this all-too-common disease. Here are some of our advances over just the past year:

TAGS: Women, Cancer, Biology, Cancer treatment

Combined Approach Offers Hope to Lung Cancer Patients Who Become Resistant to Drugs
Combined Approach Offers Hope to Lung Cancer Patients Who Become Resistant to Drugs

https://www.weizmann-usa.org/news-media/news-releases/combined-approach-offers-hope-to-lung-cancer-patients-who-become-resistant-to-drugs/

Jul 25, 2018... Response to treatment in cancer cells: The abundance of the EGFR (top row) and HER2 (bottom row) receptors is reduced when the cells are exposed to triple therapy – Tagrisso®, Erbitux®, and Herceptin® (right column) and to the two antibodies, Erbitux® and Herceptin® (second from right column), but not when they are exposed to Tagrisso® alone (second column from left) or to no therapy at all (left column)

TAGS: Cancer, Cancer treatment

Why Cancer Drugs May Work Better While You Sleep
Why Cancer Drugs May Work Better While You Sleep

https://www.weizmann-usa.org/news-media/in-the-news/why-cancer-drugs-may-work-better-while-you-sleep/

Oct 09, 2014... It’s news to no one that your body works differently when you’re awake and when you’re sleeping. But could the different states also affect how your body processes certain life-saving drugs? Researchers, reporting Friday in the journal Nature Communications, found that when it comes to cancer drugs, the answer may be yes.
Researchers at the Weizmann Institute discovered – by happy accident – that some of the body’s molecular functions during the day may interfere with the effectiveness of certain cancer medication. Specifically, they found that the normal day-time production of some steroid hormones in the body actually inhibited the work of epidermal growth factor (EGF) receptors – which are the proteins targeted by a class of anti-cancer drugs. Tumor cells plant these receptors on their surfaces to attract nutrients that help them survive and grow. Drugs, including the breast cancer agent lapatinib, can block these receptors on tumors, and such medications are a popular way to treat breast cancers expressing epidermal growth factor.

TAGS: Cancer, Biochemistry, Biology, Cancer treatment

The Transformation
The Transformation

https://www.weizmann-usa.org/news-media/in-the-news/the-transformation/

Sep 15, 2014... An experimental new drug can make some leukemic cells mature into healthier ones. Illustration by Brian Stauffer
For almost thirty years, William Kuhens worked on Staten Island as a basketball referee for the Catholic Youth Organization and other amateur leagues. At seventy, he was physically fit, taking part in twenty games a month. But in July of 2013 he began to lose weight and feel exhausted; his wife told him he looked pale. He saw his doctor, and tests revealed that his blood contained below-normal numbers of platelets and red and white blood cells; these are critical for, respectively, preventing bleeding, supplying oxygen, and combatting infection. Kuhens was sent to the Memorial Sloan Kettering Cancer Center, in Manhattan, to meet with Eytan Stein, an expert in blood disorders. Stein found that as much as fifteen per cent of Kuhens’s bone marrow was made up of primitive, cancerous blood cells. “Mr. Kuhens was on the cusp of leukemia,” Stein told me recently. “It seemed that his disease was rapidly advancing.”

TAGS: Cancer, Cancer treatment, Immunotherapy, Leukemia, Enzymes, Blood

Melanoma/Skin Cancer Research at the Weizmann Institute of Science
Melanoma/Skin Cancer Research at the Weizmann Institute of Science

https://www.weizmann-usa.org/news-media/feature-stories/melanoma-skin-cancer-research-at-the-weizmann-institute-of-science/

May 03, 2012... Do you know that skin cancer is the most common form of cancer? And that it’s on the rise, with increased incidence over the last 30 years? In fact, the American Cancer Society estimates that, in 2013, almost 77,000 new melanomas will be diagnosed in the U.S. alone, and over 9,000 people will die of the disease.
While prevention and early screening are critical, fighting skin cancer once it develops is still a challenge. That’s why researchers at the Weizmann Institute of Science are attacking skin cancer and melanoma from a number of angles, including:

TAGS: Cancer, Cancer treatment, Clinical trials

Israeli Firm Offers Hope to Cancer Patients Beyond Standard Care
Israeli Firm Offers Hope to Cancer Patients Beyond Standard Care

https://www.weizmann-usa.org/news-media/in-the-news/israeli-firm-offers-hope-to-cancer-patients-beyond-standard-care/

Mar 24, 2019... Trial-In CEO Nir Erez. (photo credit: Courtesy)
Working in the field of oncology was a case of love at first sight for Weizmann Institute of Science graduate Nir Erez.
In 2003, after completing his Master’s degree, Erez joined pharma giant Roche Pharmaceuticals (Israel), which specializes in the development and marketing of cancer drugs. There, he worked alongside leading oncologists, learned of breakthrough cancer treatments and the development and types of the disease.

TAGS: Community, Cancer, Cancer treatment, Clinical trials

EMA Approves Steba’s Prostate Cancer Drug
EMA Approves Steba’s Prostate Cancer Drug

https://www.weizmann-usa.org/news-media/in-the-news/ema-approves-steba-s-prostate-cancer-drug/

Sep 25, 2017... Raphael and Fabrice Harari
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended by a majority of 29-2 the approval for marketing of the Tookad drug for treatment of prostate cancer developed by Israeli company Steba Biotech. Tookad is a complex treatment, in which the patient takes a drug, but the drug is activated only in the area of the tumor, through the skin. The product, developed by Professor Avigdor Scherz and Dr. Yoram Salomon of the Weizmann Institute of Science, has already been approved for marketing and sale in Israel and Mexico.

TAGS: Cancer, Cancer treatment, Clinical trials

September is Prostate and Ovarian Cancer Awareness Month
September is Prostate and Ovarian Cancer Awareness Month

https://www.weizmann-usa.org/news-media/feature-stories/september-is-prostate-and-ovarian-cancer-awareness-month/

Sep 17, 2018... September is both Prostate Cancer Awareness Month and Ovarian Cancer Awareness Month in the U.S., where prostate cancer is the most common cancer (after skin cancer) in men: about 1 in 7 will be diagnosed during his lifetime. However, as the American Cancer Society points out, prostate cancer is now quite treatable, and “most men diagnosed with prostate cancer do not die from it.” But there is still progress to be made: for example, current treatments can have undesirable side effects, such as erectile dysfunction and urinary incontinence.

TAGS: Genetics, Women, Cancer, Biology, Cancer treatment

Predicting Immunotherapy Success
Predicting Immunotherapy Success

https://www.weizmann-usa.org/news-media/news-releases/predicting-immunotherapy-success/

Feb 18, 2020... REHOVOT, ISRAEL—February 18, 2020—One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.

TAGS: Cancer, Biology, Cancer treatment, Immunotherapy

First … 2 3 4 5 6 7 8 9 10 11 12 ... Last
Back Next
SHARE

Our Achievements

Learn more about remarkable Weizmann Institute achievements that are enhancing and transforming our lives.

Learn More

Support Our Flagship Projects

Help us accelerate exciting initiatives in three forward-looking fields: neuroscience, physics, and artificial intelligence.

Learn More

Newsletter

Get the latest news and breakthroughs from the Weizmann Institute of Science.

About Us
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
Our Achievements
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Get Involved
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
News & Media Blog: Curiosity Review Donate Now Contact Us
Privacy Policy Gift Acceptance Policy Financial Information

©2023 American Committee for the Weizmann Institute of Science

Charity Navigator

FOR THE FOURTH CONSECUTIVE YEAR

Platinum Transparency 2023